Pfizer says FDA permits new data on Sutent label
This new indication is based on results of a large phase III trial which showed prolonged progression-free survival. Sutent was originally approved in January 2006 for the treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.